Liposome encapsulated ganciclovir reduced the number of intravitreal injections, stabilising CMV retinitis, and warrants further study. (BrJ Ophthalmol 1994; 78: 677-680) 
Abstract
To study its safety and efficacy in treating cytomegalovirus (CMV) retinitis, an AIDS patient received an intravitreal injection of liposome encapsulated ganciclovir in the right eye. The left eye served as a control, receiving intravitreal free ganciclovir. The right eye showed no retinal haemorrhages or detachment; however, vision declined initially, stabilising later. Weekly examination showed neither progression of the CMV retinitis nor new lesions in the right eye. The left eye showed reactivation of old CMV retinitis. Liposome encapsulated ganciclovir reduced the number of intravitreal injections, stabilising CMV retinitis, and warrants further study. (BrJ Ophthalmol 1994; 78: 677-680) Cytomegalovirus (CMV) retinitis is the most common cause of visual loss in AIDS. Approx (7 16 and 8-16 mmol/l respectively). The subretinal fluid levels decreased to 0-8 mmol/l 21 hours after intravenous administration of the ganciclovir. " The advantages of intravenous ganciclovir therapy include the ability to treat bilateral disease and possible prevention or control of CMV infections at other sites. Because the role of intravenous ganciclovir in survival is unclear and systemic toxicities are associated with intravenous ganciclovir and foscarnet, the intravitreal route of administration is being studied.3 4 12-15 In rabbit eyes,'6 200-400 pg doses of ganciclovir showed no evidence of adverse electrophysiological or histopathological effect. However, high doses (155 mmol/l) in vitrectomy infusion fluids were associated with significant retinal cellular disorganisation and dissipation. Because the half life of intravitreal ganciclovir is 13-3 hours,2 frequent administration is required, leading to patient intolerance. Repeated intravitreal ganciclovir administration is associated with increased risk ofendophthalmitis, retinal detachment, vitreous haemorrhage, and increased intraocular pressure.21' 1' The incidence of bacterial endophthalmitis varied from zero in 110 injections4 to 0 4% in a series of 249. ' 
